| 4.34 0.05 (1.17%) | 04-23 15:22 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 6.06 | 1-year : | 6.73 |
| Resists | First : | 5.18 | Second : | 5.76 |
| Pivot price | 4.74  |
|||
| Supports | First : | 4.25 | Second : | 3.53 |
| MAs | MA(5) : | 4.46 |
MA(20) : | 4.85 |
| MA(100) : | 4.87  |
MA(250) : | 3.8 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 5.2 |
D(3) : | 7 |
| RSI | RSI(14): 33.3 |
|||
| 52-week | High : | 6.07 | Low : | 0.86 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BVS ] has closed above bottom band by 11.3%. Bollinger Bands are 25.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.5 - 4.53 | 4.53 - 4.55 |
| Low: | 4.19 - 4.22 | 4.22 - 4.25 |
| Close: | 4.24 - 4.3 | 4.3 - 4.33 |
Bioventus Inc. a medical device company, focuses on developing and commercializing clinical treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical joint pain injection therapies, as well as peripheral nerve stimulation products. Its surgical solutions comprise bone graft substitutes to fuse and grow bones, enhance results following spinal and other orthopedic surgeries; and ultrasonic medical devices for the use in precise bone sculpting, remove tumors, and tissue debridement. The company's restorative therapies include an ultrasonic bone healing system for fracture care; skin allografts; and products that are used to support healing of chronic wounds, as well as advanced rehabilitation devices designed to help patients regain leg or hand function. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is headquartered in Durham, North Carolina.
Wed, 27 Mar 2024
BVS Stock Quote Price and Forecast - CNN
Tue, 12 Mar 2024
Bioventus, Inc. on the Brink: Navigating Financial Control Challenges and Investor Confidence - TipRanks.com - TipRanks
Tue, 12 Mar 2024
Bioventus Surges with 7.6% Q4 Revenue Growth to $135.4M, Outstripping Expectations - The Tokenist
Tue, 12 Mar 2024
Bioventus Reports Upbeat Earnings, Joins Ranpak, Beachbody And Other Big Stocks Moving Higher On Tuesday - Markets Insider
Tue, 12 Mar 2024
Bioventus Inc. (BVS) Q4 2023 Earnings Call Transcript - Seeking Alpha
Tue, 12 Mar 2024
Bioventus Inc (BVS) Reports Growth in Q4 Sales and Adjusted EBITDA, Provides Optimistic 2024 ... - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 63 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 11.1 (%) |
| Held by Institutions | 66.3 (%) |
| Shares Short | 787 (K) |
| Shares Short P.Month | 803 (K) |
| EPS | -1.54 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.74 |
| Profit Margin | -30.5 % |
| Operating Margin | 1.9 % |
| Return on Assets (ttm) | 0.1 % |
| Return on Equity (ttm) | -38.3 % |
| Qtrly Rev. Growth | 7.5 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 8.08 |
| EBITDA (p.s.) | 0.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 15 (M) |
| Levered Free Cash Flow | -108 (M) |
| PE Ratio | -2.81 |
| PEG Ratio | 0 |
| Price to Book value | 1.57 |
| Price to Sales | 0.53 |
| Price to Cash Flow | 17.86 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|